Drug Profile
Adipose-derived autologous stem cell therapy - Kasiak Research
Alternative Names: ADMSC - Kasiak Research; ADSC - Kasiak Research; REFACELL-CLILatest Information Update: 09 Sep 2016
Price :
$50
*
At a glance
- Originator Kasiak Research
- Class Anti-ischaemics; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Peripheral arterial occlusive disorders
Most Recent Events
- 09 Sep 2016 Phase-I/II development is ongoing in India (Kasiak Research pipeline, September 2016)
- 01 May 2014 Phase-I/II clinical trials in Peripheral arterial occlusive disorders (critical limb ischaemia) in India (IV)
- 01 May 2014 Phase-I/II clinical trials in Peripheral arterial occlusive disorders (critical limb ischaemia) in India (IM)